Anap­tys­Bio's etokimab pro­vides more dis­ap­point­ing re­sults, rais­ing ques­tions about com­pound's fu­ture

The lead pro­gram for Anap­tys­Bio’s in-house pipeline has hit an­oth­er set­back.

Etokimab, an IL-33 in­hibitor, did not achieve sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in a Phase II tri­al for pa­tients suf­fer­ing from chron­ic rhi­nos­i­nusi­tis with nasal polyps. Re­searchers mea­sured the in­di­vid­u­als’ bi­lat­er­al nasal polyps score and sino-nasal out­come test, find­ing that nei­ther im­proved up­on a place­bo af­ter both four- and eight-week time mark­ers, though they did demon­strate im­prove­ment over base­line lev­els of the ex­am­i­na­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.